Perflutren

Chemical formula: Cā‚ƒFā‚ˆ  Molecular mass: 188.019 g/mol  PubChem compound: 6432

Therapeutic indications

Perflutren is indicated for:

Contrast echocardiography

Population group: only adults (18 years old or older)

Perflutren is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular endocardial border delineation with resulting improvement in wall motion visualisation. Perflutren should only be used in patients where the study without contrast enhancement is inconclusive.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Perflutren is contraindicated in the following cases:

Pulmonary hypertension (systolic pulmonary artery pressure >90 mmHg)

Severe pulmonary hypertension

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Structured Product Labeling (SPL/PLR) 2020: DEFINITY Suspension for injection
Summary of Product Characteristics (SPC) 2019: OPTISON Dispersion for injection
< Previous: Overview
Next: Precautions >

Ā© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈